Cell-free DNA (cfDNA) is short, extracellular, fragmented double-stranded DNA found in
plasma. Plasma of patients with solid tumor has been found to show significantly increased …

Background Cell-free DNA (cfDNA) extracted from blood has become a clinically feasible
biomarker in various types of cancer. However, the clinical significance of cfDNA in …

The structure of cell-free DNA (cfDNA) is altered in the blood of patients with cancer. From
whole-genome sequencing, we retrieve the cfDNA fragment-end composition using a new …

Objectives Cell free tumor DNA (cfDNA) circulating in blood has a great potential as
biomarker for cancer clinical management. The objective of this study is to evaluate if cfDNA …

Background Previous studies found that cell-free DNA (cfDNA) generated from tumors was
shorter than that from healthy cells, and selecting short cfDNA could enrich for tumor cfDNA …

Cell-free DNA (cfDNA) is easily accessible in peripheral blood and can be used as
biomarkers for cancer diagnostics, prognostics, and therapeutics. The applications of cfDNA …

The breadth of diagnostic procedures that utilize cell free DNA (cfDNA) from human plasma
has increased dramatically in recent years. Here, we confirm that tumor-derived cfDNA …

Tumor-specific, circulating cell-free DNA (cfDNA) in liquid biopsy test is a novel promising
biomarker in the advancement of cancer management, including early diagnosis, screening …

Cell-free DNA (cfDNA) analysis is a minimally invasive method that can be used to detect
genomic abnormalities by directly testing a blood sample. This method is particularly useful …

The structure, fragmentation pattern, length and terminal sequence of cell-free DNA (cfDNA)
is under the influence of nucleases present in the blood. We hypothesized that differences in …